The FDA this week released a new draft guidance encouraging the inclusion of male patients in breast cancer clinical trials, the incidence of which has increased approximately 26% over the last 25 years.
Scientific advances and regulatory incentives are driving the use of genetics in drug development, though the industry’s ability to perform wide-scale testing has outpaced its understanding of the results, the misinterpretation of which can have “disastrous”...
Belong.Life raises $14m as part of a Series B funding round with plans to expand its patient engagement platform, using and complementing Iqvia’s solutions “to transform patient engagement,” says Iqvia VP.
Saga Diagnostics AB secures venture-backed financing to advance its precision oncology genomics testing technology, which is being used to monitor patient responses in clinical trials, among other applications.
The global oncology market last year set several records, though the industry continues to struggle with long development timelines, which in 2018 averaged 10.5 years from patent filing to regulatory approval and launch, according to a recent Iqvia report.